1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: Other
Protocol IDs: MCC-14178, NCT00361140
|
|
2.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: SCT 0208, NCT00679536
|
|
3.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 4 to 70
Sponsor: Other
Protocol IDs: RPCI-RP-9815, NCI-V99-1527, NCT00003816, RP 98-15
|
|
4.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 35 and under
Sponsor: Other
Protocol IDs: 0005M52481, MT2000-12, 2000LS040, NCT00176839
|
|
5.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 12 to 55
Sponsor: Pharmaceutical / Industry
Protocol IDs: GC P#02.01.001, NCT00469729
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 75
Sponsor: NCI
Protocol IDs: FHCRC-1813.00, 5666, NCT00075478
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 65 and under
Sponsor: NCI, NHLBI
Protocol IDs: FHCRC-1992.00, 6170, NCT00322101, NHLBI-K23-HL084054-01A1
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: NCI
Protocol IDs: CBMTG-0601, NCT00438958
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 66 and over
Sponsor: NCI, NHLBI
Protocol IDs: 418, BMTCTN-0201, NCT00075816
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to 21
Sponsor: NCI, NHLBI
Protocol IDs: 467, BMT CTN 0501, 5 U01 HL69294-05, NCT00412360
|
|
11.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 65 and under
Sponsor: Other
Protocol IDs: 2005-0366, NCT00469144
|
|
12.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 2 to 55
Sponsor: NCI, NHLBI
Protocol IDs: 385, BMT CTN 0402, U01 HL069294-05, NCT00406393
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR013651, EPOANE3018, NCT00695396
|
|
14.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E2905, E2905, NCT00843882
|
|
15.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2008-0503, NCT00887068
|
|
16.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 4 to 21
Sponsor: NCI
Protocol IDs: NCI-01-C-0125F, NCT00020592
|
|
17.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: FHCRC-1803.00, 5606, NCT00068718
|
|
18.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: H8713, NCT00058825
|
|
19.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 12 to 60
Sponsor: Pharmaceutical / Industry
Protocol IDs: CB001, NCT00089596
|
|
20.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Under 75
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: FHCRC-1825.00, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
|
|
21.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 16 to 50
Sponsor: Other
Protocol IDs: FHCRC-1809.00, 5602, NCT00119366
|
|
22.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 72
Sponsor: NHLBI
Protocol IDs: NHLBI-05-H-0206, NCT00217594
|
|
23.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI
Protocol IDs: OHSU-HEM-05011-L, OHSU-210, NCT00245037
|
|
24.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Older patients
Sponsor: NCI, Other
Protocol IDs: BMT124, 75117, BMT124, NCT00185692, NCT00185692
|
|
25.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: ECP RIT, NCT00179790
|
